4D Molecular Therapeutics (NASDAQ:FDMT) Downgraded by Wall Street Zen to “Sell”

by · The Cerbat Gem

Wall Street Zen cut shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) from a hold rating to a sell rating in a research note published on Saturday.

Other analysts have also issued reports about the stock. Roth Capital lowered their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Barclays decreased their price objective on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada raised their target price on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 11th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $28.70.

Check Out Our Latest Research Report on FDMT

4D Molecular Therapeutics Stock Performance

FDMT opened at $10.70 on Friday. The stock’s 50 day moving average price is $10.37 and its 200-day moving average price is $7.06. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $12.34. The stock has a market cap of $611.29 million, a price-to-earnings ratio of -2.85 and a beta of 2.96.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. As a group, analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 2,678 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the transaction, the insider owned 3,594 shares of the company’s stock, valued at $43,128. The trade was a 42.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 10,763 shares of company stock worth $109,415 over the last 90 days. Company insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth $41,000. Farther Finance Advisors LLC grew its stake in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter. Abich Financial Wealth Management LLC bought a new position in 4D Molecular Therapeutics in the third quarter worth about $80,000. Inscription Capital LLC bought a new position in 4D Molecular Therapeutics in the third quarter worth about $94,000. Finally, Impact Partnership Wealth LLC purchased a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at about $96,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

Further Reading